<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pharmacology of cyclosporine and tacrolimus</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pharmacology of cyclosporine and tacrolimus</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pharmacology of cyclosporine and tacrolimus</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karen Hardinger, PharmD, BCPS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Colm C Magee, MD, MPH, FRCPI</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel E Furst, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel C Brennan, MD, FACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 24, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> selectively inhibit calcineurin, thereby impairing the transcription of interleukin (IL)-2 and several other cytokines in T lymphocytes. Calcineurin inhibitors have been mainstays of immunosuppression in solid organ transplantation for over three decades.</p><p><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> are occasionally used in the treatment of various immune-mediated diseases. However, concerns about their long-term toxicity (especially kidney function impairment and hypertension) and the availability of newer biologic agents have restricted the use of cyclosporine and tacrolimus to patients who have not responded to conventional treatment. The kidney toxicity of these agents is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7357.html" rel="external">"Cyclosporine and tacrolimus nephrotoxicity"</a>.)</p><p>The pharmacology of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> is reviewed here. The efficacy and use of these agents in specific conditions, including organ transplantation and immune-mediated diseases, are discussed separately in the topic reviews addressing the treatment of each disorder. (See appropriate topic reviews.)</p><p class="headingAnchor" id="H3"><span class="h1">MECHANISM OF ACTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> is a lipophilic cyclic peptide of 11 amino acids, while <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> is a macrolide antibiotic. Both drugs have been isolated from fungi and possess similar suppressive effects on cell-mediated and humoral immune responses.</p><p>Both drugs bind with high affinity to a family of cytoplasmic proteins present in most cells: cyclophilins for <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and FK-binding proteins for <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>. The drug-receptor complex specifically and competitively binds to and inhibits calcineurin, a calcium- and calmodulin-dependent phosphatase [<a href="#rid1">1-4</a>]. This process inhibits the translocation of a family of transcription factors (NF-AT), leading to reduced transcriptional activation of cytokine genes for interleukin (IL)-2, tumor necrosis factor (TNF)-alpha, IL-3, IL-4, CD40L, granulocyte-macrophage colony-stimulating factor, and interferon-gamma [<a href="#rid1">1,2,5,6</a>]. Ultimately, proliferation of T lymphocytes is reduced.</p><p><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> act primarily on T helper cells, although some inhibition of T suppressor and T cytotoxic cells may also occur. Cyclosporine also increases the expression of transforming growth factor (TGF)-beta, which may be an important mechanism by which it causes kidney fibrosis [<a href="#rid7">7,8</a>]. Unlike some other immunosuppressive agents, such as <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> and the alkylating agents, cyclosporine and tacrolimus do not cause clinically significant myelosuppression [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H4"><span class="h1">FORMULATIONS</span><span class="headingEndMark"> — </span>Oral, intravenous, and ophthalmic formulations of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> are available  (<a class="graphic graphic_table graphicRef57518" href="/z/d/graphic/57518.html" rel="external">table 1</a>). Oral, intravenous, and topical formulations of <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> are available. The intravenous forms of both drugs should be used only if enteral administration is not possible, because there is the potential for greater toxicity with intravenous administration. Generic forms of cyclosporine and tacrolimus are available in many countries, including the United States. In general, patients stabilized on one preparation should not be switched to another, because there are concerns about differences in pharmacokinetics. If a conversion between preparations is necessary, monitoring trough concentrations should be performed until the results are stable [<a href="#rid10">10</a>]. (See <a class="local">'Switching formulations'</a> below.)</p><p class="headingAnchor" id="H2290697752"><span class="h2">Cyclosporine</span><span class="headingEndMark"> — </span>Oral, intravenous, and ophthalmic formulations of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> are available.</p><p><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> is available in nonmodified and modified formulations. Nonmodified oral cyclosporine depends upon bile for absorption and has erratic gastrointestinal absorption patterns. Modified cyclosporine, a microemulsion formulation, does not depend upon bile salts for absorption and exhibits increased bioavailability and more consistent absorption.</p><p class="headingAnchor" id="H5"><span class="h3">Nonmodified</span><span class="headingEndMark"> — </span>Liquid <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> is available in capsules, oral solution, and concentrate for injection:</p><p class="bulletIndent1"><span class="glyph">●</span>Liquid-filled capsules of 25 mg and 100 mg are stored at less than 86°F (30°C) but not frozen.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The oral solution of 100 mg/mL in 50 mL bottles remains stable for two months after opening if stored in the original container at less than 86°F (30°C) but does not require refrigeration and should not be frozen.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Concentrate for injection of 50 mg/mL in 5 mL ampules should be stored at less than 86°F (30°C) and protected from light and freezing. Dilutions in 5 percent glucose or normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> are stable for 24 hours. Substantial amounts of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> may be lost during intravenous administration through plastic tubing. Polyoxyethylated castor oil that is contained in the concentration for intravenous cyclosporine infusion can cause phthalate stripping from polyvinyl chloride (PVC)-containing intravenous tubing. Thus, when intravenous nonmodified cyclosporine is administered, PVC-free intravenous fluid containers and tubing should be used.</p><p></p><p class="headingAnchor" id="H6"><span class="h3">Modified</span><span class="headingEndMark"> — </span>Capsules and solution are for oral use; no parenteral formulation is available. Patients who need an intravenous formulation should be prescribed <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> nonmodified concentrate for injection. Cyclosporine modified capsules or the equivalent generic product are preferred due to superior pharmacokinetic profile compared with the nonmodified formulation:</p><p class="bulletIndent1"><span class="glyph">●</span>Capsules of 25 mg and 100 mg should be stored at 68 to 77°F (20 to 25°C); some generic formulations are available in a 50 mg capsule.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The oral solution of 100 mg/mL is available in 50 mL bottles, which remains stable for two months after opening if stored in the original container at 68 to 77°F (20 to 25°C).</p><p></p><p class="headingAnchor" id="H7"><span class="h3">Ophthalmic emulsion</span><span class="headingEndMark"> — </span>An ophthalmic emulsion of 0.05 percent is available in single vials of 0.4 mL and stored at 59 to 77°F (15 to 25°C).</p><p class="headingAnchor" id="H8"><span class="h2">Tacrolimus</span><span class="headingEndMark"> — </span>Oral, intravenous, and topical formulations of <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> are available.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">Tacrolimus</a> immediate-release capsules of 0.5 mg, 1 mg, and 5 mg are stored at 59 to 86°F (15 to 30°C).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extended-release capsules (Astagraf XL/Advagraf) of 0.5 mg, 1 mg, and 5 mg are stored at 59 to 86°F (15 to 30°C). They should not be crushed or chewed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extended-release tablets (Envarsus XR) of 0.75 mg, 1 mg, and 4 mg are stored at 59 to 86°F (15 to 30°C). They should not be crushed or chewed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">Tacrolimus</a> concentrate for injection of 5 mg/mL in 1 mL ampules is stored at 41 to 77°F (5 to 25°C) and is stable for 24 hours in plastic syringes at 75°F (24°C). When diluted in glucose or <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> solutions, it remains stable for 24 hours in glass, but not PVC, containers.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">Tacrolimus</a> ointment of 0.03 and 0.1% in 30 g and 60 g tubes are stored at 41 to 77°F (5 to 25°C).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">Tacrolimus</a> granules (used to make a suspension) of 0.2 and 1 mg unit-dose packets are stored at 68 to 77°F (20 to 25°C). Tubing, syringes, and other equipment (cups) containing PVC should not be used to prepare or administer tacrolimus products. The suspension should be given immediately after preparation and not stored.</p><p></p><p>There are two extended-release formulations of <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> designed for once-daily administration. Their mechanisms of prolonged release and pharmacokinetic profiles differ; therefore, the two are not interchangeable. The extended-release tacrolimus <strong>capsule</strong> (Astagraf XL/Advagraf) is a modified-release formulation that allows slow release of the drug by controlling water penetration and forming a protective polymer gel layer around tacrolimus [<a href="#rid11">11</a>]. The extended-release tacrolimus <strong>tablet</strong> (Envarsus XR) uses a drug-delivery technology that improves the bioavailability of drugs with low water solubility [<a href="#rid12">12</a>].</p><p>Extended-release <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> capsules (Astagraf XL/Advagraf) are not approved in liver transplantation due to an increase in mortality in female liver transplant recipients [<a href="#rid13">13</a>]. </p><p>Short courses of sublingual <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> have been used as an alternative to intravenous tacrolimus when enteral administration is not possible [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H2230178526"><span class="h1">DOSE AND ADMINISTRATION</span></p><p class="headingAnchor" id="H3004379546"><span class="h2">Administration</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cyclosporine</strong><strong> </strong>– <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> should be administered at a consistent time of the day (at 12-hour intervals), and with a consistent relation to meals, in order to decrease the intra-individual blood concentration variations.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> nonmodified oral solution should be mixed with milk, chocolate milk, or orange juice at room temperature. Cyclosporine modified oral solution should be mixed with water, orange juice, or apple juice.</p><p></p><p class="bulletIndent1">Both <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> solutions may adhere to plastic and therefore should not be mixed in a plastic cup or with plastic utensils. If a dose is missed, patients should take it as soon as possible, ideally within four hours. They should not double the next dose.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tacrolimus</strong><strong> </strong>– <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">Tacrolimus</a> immediate-release should be administered at a consistent time of the day (at 12-hour intervals) and preferably on an empty stomach. The extended-release products should be taken at the same time of the day, preferably in the morning. Patients should not chew, divide, or crush the tablets.</p><p></p><p class="bulletIndent1">If an immediate-release <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> dose is missed, patients should take it as soon as possible, ideally within four hours.</p><p></p><p class="bulletIndent1">For the extended-release product, if a dose is missed, patients should take it as soon as possible within 14 to 15 hours after missing the dose. After the 14- to 15-hour timeframe, patients should wait until the usual scheduled time to take the next daily dose. Patients should not double the next dose. Patients should avoid alcoholic beverages while taking the extended-release product. Consumption of alcohol may increase the release rate of <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> and/or adversely alter the pharmacokinetic properties and the effectiveness and safety of the extended-release product [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1">Tubing, syringes, and other equipment (cups) containing PVC should not be used when preparing or administering <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> granule products [<a href="#rid16">16</a>]. To prepare the dose, patients should empty the entire contents of each granules packet into a glass cup. The granules should then be mixed with 1 to 2 tablespoons (15 to 30 mL) of room temperature drinking water. The granules will not completely dissolve. The suspension should be taken immediately after preparation. The cup or non-PVC syringe should be rinsed with the same quantity of water (15 to 30 mL) and given to the patient to ensure that all of the medication is taken. Wearing disposable gloves is recommended during dilution of the injection or when preparing the oral suspension in the hospital and when wiping any spills. Inhalation or direct contact with skin or mucous membranes of the powder or granules should be avoided. If such contact occurs, the skin should be washed thoroughly with soap and water; if ocular contact occurs, eyes should be rinsed with water. In case a spill occurs, the surface should be wiped with a wet paper towel. Granules should not be sprinkled on food.</p><p></p><p class="headingAnchor" id="H3680755668"><span class="h2">Dose</span><span class="headingEndMark"> — </span>The dose and target concentrations of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> vary with the disease being treated. The doses used in patients with solid organ transplants are discussed below. Other diseases are discussed elsewhere in the appropriate topic reviews.</p><p>Initial doses of calcineurin inhibitors should be determined by taking into account drug interactions, diet, time after transplantation, pharmacokinetics, presence of infection, drug toxicity, and/or rejection. Drug concentration monitoring should occur after the initial doses are given. (See <a class="local">'Drug monitoring'</a> below.)</p><p>Most centers start calcineurin inhibitor therapy just before transplantation or within the first 24 hours of transplantation (see  <a class="medical medical_review" href="/z/d/html/7353.html" rel="external">"Kidney transplantation in adults: Induction immunosuppressive therapy"</a>). Some centers delay the introduction of a calcineurin inhibitor until the serum creatinine has decreased by 50 percent from the pretransplant value or the patient has significant urine output. However, there is little evidence that delayed, rather than immediate, initiation of a calcineurin inhibitor results in lower rates of delayed graft function [<a href="#rid17">17,18</a>].</p><p>In addition, the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend that administration of calcineurin inhibitors should not be delayed until the onset of graft function [<a href="#rid19">19</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cyclosporine</strong><strong> modified </strong>– For nonautoimmune disease, <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> modified is initially dosed at 4 to 10 mg/kg/day orally in two divided doses. Most clinicians start at the lower end of the dosing range and make adjustments based upon drug concentrations. The first dose may be administered within 24 hours of transplantation. In newly transplanted patients, the initial dose of cyclosporine modified is the same as the initial dose of cyclosporine nonmodified, although cyclosporine modified is preferred.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tacrolimus</strong><strong> </strong>– <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">Tacrolimus</a> is typically dosed at 0.1 to 0.2 mg/kg/day orally in two divided doses. Most clinicians start at the lower end of the dosing range and make adjustments based upon drug concentrations. The product information recommends the following for tacrolimus initiation [<a href="#rid16">16</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>At 0.1 mg/kg/day in kidney transplant recipients who also receive <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil plus an interleukin (IL)-2 receptor antagonist</p><p class="bulletIndent2"><span class="glyph">•</span>At 0.2 mg/kg/day in kidney transplant recipients treated with <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> rather than <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil</p><p class="bulletIndent2"><span class="glyph">•</span>At 0.1 to 0.15 mg/kg/day in adult liver transplant recipients</p><p class="bulletIndent2"><span class="glyph">•</span>At 0.075 mg/kg/day in adult heart and lung transplant recipients</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extended-release </strong><strong>tacrolimus</strong><strong> products</strong> – In patients receiving <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, glucocorticoids, and <a class="drug drug_general" data-topicid="8803" href="/z/d/drug information/8803.html" rel="external">basiliximab</a> induction, extended-release <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> capsules (Astagraf XL/Advagraf) should be given at a dose of 0.15 to 0.2 mg/kg/day prior to reperfusion or within 48 hours of the completion of the transplant procedure. In patients treated with mycophenolate mofetil and glucocorticoids without basiliximab induction, extended-release tacrolimus capsules should be given as a single dose of 0.1 mg/kg within 12 hours prior to reperfusion, then 0.2 mg/kg at least 4 hours after the preoperative dose, and within 12 hours after reperfusion, then 0.2 mg/kg daily [<a href="#rid13">13</a>]. The recommended starting dose of extended-release tacrolimus tablets (Envarsus) in de novo kidney transplant patients is 0.14 mg/kg/day with antibody induction [<a href="#rid20">20</a>].</p><p></p><p class="headingAnchor" id="H2121343288"><span class="h2">Drug monitoring</span><span class="headingEndMark"> — </span>Therapeutic monitoring of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> is complicated by the narrow margin between adequate immunosuppression and toxicity. Whole blood should be used as a sample for both drugs. A variety of assays are available, and clinicians should become familiar with the one used in their local laboratory.</p><p><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> should be monitored using 12-hour trough (C0), two-hour post-dose (C2), or abbreviated area under the time concentration curve (AUC) [<a href="#rid19">19</a>]. Although monitoring of C0 is common practice, there is a poor correlation with safety, efficacy, and drug exposure using this strategy. Some centers use C2 monitoring among kidney transplant recipients since these concentrations may correlate more closely with exposure, and higher C2 concentrations have been associated with decreased acute rejection rates in the first year [<a href="#rid21">21-23</a>]. In one study of liver transplant patients, C2 was more closely associated with the first four-hour post-dose cyclosporine exposure (AUC0-4) than C0 [<a href="#rid24">24</a>]. C2 monitoring may be more accurate but is often more difficult and less convenient for the patient. Most centers monitor either C0 or C2 concentrations but not both. In rare circumstances, assessing both may be beneficial in a patient with absorption issues.</p><p><a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">Tacrolimus</a> should be monitored using 12- and 24-hour trough (C0) concentrations for the immediate-release and extended-release preparations, respectively [<a href="#rid19">19</a>].</p><p>Blood concentrations should be checked two to three days after starting <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> and after any dose change. Typically, after transplant, concentrations are measured every one or two days while hospitalized. After discharge, levels should be measured once or twice weekly for the first month, then weekly until three months posttransplantation, then every two weeks until six months posttransplant, and then monthly. Some stable, low-risk patients may have concentrations monitored every two to three months. However, if drugs that affect cyclosporine or tacrolimus metabolism are added or withdrawn, more frequent measurement of trough concentrations will be required (see <a class="local">'Food and drug interactions'</a> below). Tacrolimus and cyclosporine reach steady-state concentrations after four to six doses.</p><p class="headingAnchor" id="H663902893"><span class="h2">Target concentrations</span><span class="headingEndMark"> — </span>Target concentrations for <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> vary depending upon which disease is being treated. These recommendations are presented elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>In kidney transplant recipients (see  <a class="medical medical_review" href="/z/d/html/7356.html" rel="external">"Kidney transplantation in adults: Maintenance immunosuppressive therapy"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In lung transplant recipients (see  <a class="medical medical_review" href="/z/d/html/16734.html" rel="external">"Maintenance immunosuppression following lung transplantation", section on 'Calcineurin inhibitors'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In liver transplant recipients (see  <a class="medical medical_review" href="/z/d/html/4586.html" rel="external">"Liver transplantation in adults: Initial and maintenance immunosuppression", section on 'Calcineurin inhibitors'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In heart transplant recipients (see  <a class="medical medical_review" href="/z/d/html/3530.html" rel="external">"Heart transplantation in adults: Induction and maintenance of immunosuppressive therapy", section on 'Calcineurin inhibitors'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In hematopoietic cell transplant recipients (see  <a class="medical medical_review" href="/z/d/html/3542.html" rel="external">"Prevention of graft-versus-host disease", section on 'Calcineurin inhibitors (CNI)'</a> and  <a class="medical medical_review" href="/z/d/html/3543.html" rel="external">"Treatment of acute graft-versus-host disease"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In glomerular diseases (see  <a class="medical medical_review" href="/z/d/html/3051.html" rel="external">"Membranous nephropathy: Treatment and prognosis", section on 'Calcineurin inhibitors'</a> and  <a class="medical medical_review" href="/z/d/html/6130.html" rel="external">"Treatment of idiopathic nephrotic syndrome in children"</a> and  <a class="medical medical_review" href="/z/d/html/3045.html" rel="external">"Minimal change disease: Treatment in adults", section on 'Glucocorticoid-sparing regimens'</a> and  <a class="medical medical_review" href="/z/d/html/3100.html" rel="external">"Focal segmental glomerulosclerosis: Treatment and prognosis", section on 'Calcineurin inhibitors as alternative initial therapy'</a> and  <a class="medical medical_review" href="/z/d/html/117983.html" rel="external">"Steroid-resistant nephrotic syndrome in children: Management", section on 'Immunosuppressive therapy'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In inflammatory bowel diseases (see  <a class="medical medical_review" href="/z/d/html/4068.html" rel="external">"Management of the hospitalized adult patient with severe ulcerative colitis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In autoimmune diseases (see  <a class="medical medical_review" href="/z/d/html/5175.html" rel="external">"Chronic immunotherapy for myasthenia gravis", section on 'Glucocorticoid-sparing therapy'</a>)</p><p></p><p class="headingAnchor" id="H1389766250"><span class="h2">Dose adjustments</span><span class="headingEndMark"> — </span>In clinical practice, dose adjustments are made in small increments with subsequent drug concentration monitoring. If a <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> concentration is high, then the dose of cyclosporine may be lowered by 25 to 50 mg per dose. If the concentration is low, then the dose may be increased by 25 to 50 mg per dose. For <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, dose adjustments are typically 0.5 to 1 mg per dose. If a drug concentration is supratherapeutic (eg, C0 &gt;400 ng/mL for cyclosporine or &gt;20 ng/mL for tacrolimus), then the dose may be held until the concentration returns to the therapeutic range. It is important to determine whether the concentration was obtained correctly before making any dose adjustments. Tacrolimus and cyclosporine reach steady-state concentrations after four to six doses, and therefore, dose adjustments can be assessed via drug concentration monitoring two to three days after an adjustment. In addition, safety and efficacy should be monitored after adjustments.</p><p>Optimal dosing and concentrations may be affected by several factors including pharmacokinetic factors, presence of infection, drug toxicity, and/or rejection  (<a class="graphic graphic_table graphicRef106494" href="/z/d/graphic/106494.html" rel="external">table 2</a>) (see  <a class="medical medical_review" href="/z/d/html/7356.html" rel="external">"Kidney transplantation in adults: Maintenance immunosuppressive therapy"</a> and  <a class="medical medical_review" href="/z/d/html/7358.html" rel="external">"Kidney transplantation in adults: Treatment of acute T cell-mediated (cellular) rejection"</a>). Testing for polymorphisms of the multidrug resistance-1 (P-glycoprotein) and <em>CYP3A5</em> genes may aid in the dosing of calcineurin inhibitors [<a href="#rid25">25-30</a>], but large, well-designed trials are needed to determine if testing improves outcomes and is cost effective.</p><p class="headingAnchor" id="H1576783646"><span class="h2">Switching formulations</span><span class="headingEndMark"> — </span>When switching formulations of products, drug concentrations should be closely monitored for several weeks. The frequency of monitoring should depend upon several factors  (<a class="graphic graphic_table graphicRef106494" href="/z/d/graphic/106494.html" rel="external">table 2</a>), as well as how far the patient is from transplant. In a stable patient who is more than six months posttransplant, we monitor drug concentrations weekly for two to three weeks. The dose should subsequently be adjusted to attain the preconversion blood concentration. In addition, safety and efficacy should be monitored after conversion.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cyclosporine</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Oral to intravenous administration – For patients unable to take oral <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, the intravenous dose should equal one-third of the oral dose. Intravenous administration should occur over at least two to six hours twice daily in a well-hydrated patient to avoid nephrotoxicity.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nonmodified to modified formulation – In general, modified formulations of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> lead to higher area under the time concentration curve (AUC) than nonmodified preparations. Thus, patients stabilized on either form should generally not be switched from one to the other. If patients are switched, a 1:1 ratio is recommended when converting from the nonmodified to the modified formulation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> to <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> –<strong> </strong>Clinicians use a 40:1 ratio when converting from cyclosporine to tacrolimus. As an example, if a patient takes 125 mg of modified cyclosporine twice daily (250 mg/day), then a tacrolimus dose of 3 mg twice daily (6 mg/day) would be appropriate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tacrolimus</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Oral to intravenous administration – For patients unable to take oral <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, the intravenous dose should equal one-third to one-fifth of the oral daily dose and should be given as a continuous 24-hour infusion.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Immediate-release to extended-release <strong>capsules</strong> – A 1:1 conversion from immediate-release <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> to extended-release tacrolimus capsules (Astagraf XL/Advagraf) has been proven equivalent. The ratio of exposure (AUC0-24) of extended-release tacrolimus capsules to immediate-release tacrolimus twice daily is approximately 90 percent across various conversion studies in kidney, liver, and heart transplant recipients; however, in liver transplant patients, the extended-release tacrolimus capsule AUC was significantly lower in the early posttransplant period compared with that of tacrolimus twice daily [<a href="#rid29">29,31-36</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Immediate-release to extended-release <strong>tablets</strong> – Eighty percent of the total daily dose of immediate-release <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> should be used when converting to extended-release tablets (Envarsus XR) [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Oral immediate-release to sublingual immediate-release <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> – To convert from oral tacrolimus to sublingual tacrolimus, the oral tacrolimus dose should be decreased by 50 percent [<a href="#rid14">14,38</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Granules – To convert from granules to capsules or from capsules to granules, the total daily dose should remain the same [<a href="#rid16">16</a>].</p><p></p><p class="headingAnchor" id="H9"><span class="h1">PHARMACOKINETICS</span></p><p class="headingAnchor" id="H10"><span class="h2">Absorption</span><span class="headingEndMark"> — </span>Oral <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> are only partially absorbed with large inter- and intra-individual variability. Cyclosporine and tacrolimus are absorbed in the small intestine, and peak blood concentrations occur after one to eight hours. The oral bioavailability is limited for both drugs (roughly 20 percent for tacrolimus) as a result of poor absorption, partial metabolism by enzymes in the bowel mucosa, intestinal P-glycoprotein (P-gp) efflux, and first-pass hepatic metabolism [<a href="#rid39">39-42</a>]. In general, modified formulations of cyclosporine lead to higher area under the time concentration curve (AUC) than the nonmodified preparations.</p><p>In healthy volunteers, the oral bioavailability of extended-release <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> tablets was approximately 50 percent higher as compared with tacrolimus immediate-release at steady state [<a href="#rid37">37</a>]. Both extended-release tacrolimus products exhibit chronopharmacokinetic effects; evening administration, compared with morning dosing, results in a 15 percent lower AUC for extended-release tacrolimus tablets and a 35 percent lower AUC for extended-release tacrolimus capsules [<a href="#rid13">13,37</a>]. Thus, both products should be taken consistently every morning.</p><p>Pharmacokinetic trials comparing extended-release <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> formulations with immediate-release tacrolimus have demonstrated a decreased maximum concentration (Cmax) and delayed time to maximum concentration with extended-release formulations. However, extended-release tacrolimus tablets have an AUC0-24 (area under the time concentration curve from 0 to 24 hours) that is comparable with that of immediate-release tacrolimus; extended-release tacrolimus capsules have an AUC0-24 that is higher than that of immediate-release tacrolimus [<a href="#rid13">13,37</a>].</p><p>The absorption and metabolism of calcineurin inhibitors may vary with race and ethnicity. As an example, the mean <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> exposure after a single 5 mg oral dose in healthy Hispanic and African American individuals was 18 and 39 percent less, respectively, than in White individuals [<a href="#rid43">43</a>]. Similar results have been seen with the extended-release products [<a href="#rid13">13,37</a>]. Such variation may be related to differences in the frequency of polymorphisms in the <em>CYP3A5 </em>gene among African American, Hispanic, and White transplant recipients [<a href="#rid44">44-46</a>].</p><p>The absorption of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, but not <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, is dependent upon bile salts. Thus, cyclosporine modified or tacrolimus may be preferable in patients with biliary diversion or cholestasis. Cyclosporine modified absorption is decreased modestly when ingested with a fatty meal  (<a class="graphic graphic_table graphicRef109680" href="/z/d/graphic/109680.html" rel="external">table 3</a>). Similarly, tacrolimus absorption is decreased if administered after a fatty meal and should be taken on an empty stomach, if possible [<a href="#rid47">47</a>].</p><p>Patients receiving long-term <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> ophthalmic emulsion of 0.05 percent had no detectable blood cyclosporine concentrations, indicating no significant systemic absorption [<a href="#rid48">48</a>].</p><p>Topical <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> is minimally absorbed in patients with normal skin, but clinically significant absorption has been reported when used in patients with skin disease [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Distribution</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> are lipophilic and undergo extensive body distribution. In the blood, most of the absorbed amount of each drug is taken up by erythrocytes. In the plasma, cyclosporine binds mainly to lipoproteins, whereas tacrolimus binds to proteins, primarily albumin and alpha-1-acid glycoprotein. The plasma protein binding of tacrolimus is approximately 99 percent and is independent of concentration over a range of 5 to 50 ng/mL.</p><p>The highest tissue <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> concentration is achieved in the thymus, spleen, lymph nodes, bone marrow, liver, pancreas, kidney, adrenal glands, lung, and skin. <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">Tacrolimus</a> accumulates mainly in the lung, spleen, heart, kidney, and pancreas.</p><p><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> penetrates well into synovial fluid but does not cross the blood-brain barrier. Both drugs cross the placenta and appear to some extent in breast milk, but actual toxicity in breastfed infants appears to be rare [<a href="#rid50">50</a>]. Some centers measure cyclosporine and/or <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> blood concentrations in breastfed infants to confirm that these are low.</p><p class="headingAnchor" id="H12"><span class="h2">Metabolism</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> are <strong>extensively</strong> metabolized by cytochrome P-450 CYP3A enzymes in the liver. There is also some metabolism in the gut mucosa. Cyclosporine metabolism is age dependent, with a 1.5- to 2.5-fold increase in half-life in adults compared with children. Liver dysfunction also prolongs the half-life of both cyclosporine and tacrolimus. The most active cyclosporine metabolites have only 10 to 20 percent of the drug's immunosuppressive activity. By comparison, one of the metabolites of tacrolimus possesses equal immunosuppressive potency to the parent drug.</p><p class="headingAnchor" id="H13"><span class="h2">Elimination</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> are excreted in the bile. The elimination half-life can vary significantly among patients, especially with cyclosporine nonmodified, but is approximately 19 hours for cyclosporine modified and 12 hours for immediate-release tacrolimus. The elimination half-life of extended-release tacrolimus tablets after oral administration of 2 mg once daily for 10 days was 31±8 hours in healthy subjects [<a href="#rid37">37</a>]. The elimination half-life of extended-release tacrolimus capsules after oral administration of 4 mg capsules daily for 10 days was 38±3 hours in healthy subjects [<a href="#rid13">13</a>]. </p><p class="headingAnchor" id="H14"><span class="h2">Food and drug interactions</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Food interactions</strong> – The presence, composition, and timing of food may affect the absorption of many of the immunosuppressive drugs  (<a class="graphic graphic_table graphicRef109680" href="/z/d/graphic/109680.html" rel="external">table 3</a>). Because the avoidance of food at the time of medication administration is not always practical, many clinicians recommend that patients be consistent and always take their medication in the same manner, whether it is with or without food.</p><p></p><p class="bulletIndent1">A group of active chemical compounds in grapefruit, known as the furanocoumarins, are potent inhibitors of cytochrome P-450 3A4 enzyme. Grapefruit or grapefruit juice can result in an increase in systemic exposure to <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>. It is important to educate patients about the interaction between grapefruit/grapefruit juice and their immunosuppressive agents. Patients should be counseled to completely avoid grapefruit and grapefruit juice when being treated with cyclosporine or tacrolimus. In patients who refuse to avoid grapefruit and grapefruit juice, more frequent monitoring of blood cyclosporine or tacrolimus concentrations is required.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug interactions</strong> – There are multiple interactions between calcineurin inhibitors and commonly used medications. General principles of these drug interactions are reviewed here. More detailed discussions of drug interactions are found elsewhere.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Since <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> are substrates of cytochrome P-450 3A4/5 (CYP3A4/5) drug metabolism and P-glycoprotein (P-gp) transport, and cyclosporine also inhibits P-gp, any drug that affects CYP3A4 metabolism or P-gp transport, including other substrates, can potentially interact with calcineurin inhibitors  (<a class="graphic graphic_table graphicRef110436" href="/z/d/graphic/110436.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef73326" href="/z/d/graphic/73326.html" rel="external">table 6</a>). A common example is the prescribing of macrolides for respiratory tract infections: acute cyclosporine and tacrolimus toxicity may occur due to CYP3A4/5 and/or P-gp inhibition. In addition, <a class="drug drug_general" data-topicid="9208" href="/z/d/drug information/9208.html" rel="external">carvedilol</a> inhibits P-gp and may increase the blood concentrations of cyclosporine and tacrolimus [<a href="#rid51">51</a>]. </p><p></p><p class="bulletIndent2">If a patient cannot avoid a strong or moderate inhibitor/inducer of CYP3A4/5 or P-gp, then drug concentrations and toxicities must be closely monitored. Limited data are available regarding precise dose adjustments when interacting medications are coadministered with <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>. Specific drug interactions may be determined using the <a class="external" href="/drug-interactions">drug interactions program</a> embedded in UpToDate.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Clinicians may take advantage of drug interactions to lower the dose of the calcineurin inhibitor or to enhance the drug concentration. The effects of <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a> and <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">ketoconazole</a> on <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> metabolism have led to their use in transplant recipients as a method of lowering the total dose and cost of cyclosporine or tacrolimus therapy [<a href="#rid52">52,53</a>]. (See  <a class="medical medical_review" href="/z/d/html/7356.html" rel="external">"Kidney transplantation in adults: Maintenance immunosuppressive therapy"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Drugs that affect gastrointestinal motility or emptying (eg, prokinetic agents) may affect absorption of calcineurin inhibitors. <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">Metoclopramide</a>, for example, may reduce oral <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> absorption by accelerating their passage through the intestine. By contrast, narcotics may prolong transit time in the intestine, increasing the time for absorption.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Concomitant administration of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> with other potentially nephrotoxic drugs (eg, nonsteroidal antiinflammatory drugs) should be avoided because increased toxicity may result. Since calcineurin inhibitors may produce or worsen hyperkalemia, serum potassium levels should be monitored closely in patients concomitantly taking drugs that may increase potassium (eg, <a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">amiloride</a>, <a class="drug drug_general" data-topicid="10016" href="/z/d/drug information/10016.html" rel="external">triamterene</a>, and <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a>). (See  <a class="medical medical_review" href="/z/d/html/7357.html" rel="external">"Cyclosporine and tacrolimus nephrotoxicity"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Divalent cations may influence the absorption of <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>. In a single-dose, crossover study in healthy volunteers, coadministration of tacrolimus and <a class="drug drug_general" data-topicid="8614" href="/z/d/drug information/8614.html" rel="external">aluminum hydroxide-magnesium hydroxide</a> resulted in a 21 percent increase in the mean tacrolimus area under the curve (AUC) and a 10 percent decrease in the mean tacrolimus Cmax relative to tacrolimus administration alone [<a href="#rid16">16</a>]. However, in another study, patients did not require tacrolimus dose adjustment when magnesium/aluminum was prescribed with tacrolimus therapy [<a href="#rid54">54</a>]. To minimize these potential interactions, magnesium- and aluminum-containing products should not be administered within two hours of tacrolimus products, and tacrolimus drug concentrations should be closely monitored.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Several antiviral medications are being evaluated or have already been approved for treatment of coronavirus disease 2019 (COVID-19). Clinicians should be aware that these medications could interact with <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, and if these immunosuppressants are continued during COVID-19 infection, their levels should be frequently monitored. <a class="drug drug_general" data-topicid="134695" href="/z/d/drug information/134695.html" rel="external">Nirmatrelvir-ritonavir</a><strong>, for example, can dramatically increase cyclosporine and tacrolimus concentrations and associated toxicity. </strong>(See  <a class="medical medical_review" href="/z/d/html/127582.html" rel="external">"COVID-19: Issues related to solid organ transplantation", section on 'Drug-drug interactions'</a>.)</p><p></p><p class="bulletIndent1">For additional information on drug interactions, use the <a class="external" href="/drug-interactions">drug interactions program</a> provided by UpToDate.</p><p></p><p class="headingAnchor" id="H17"><span class="h1">SIDE EFFECTS</span><span class="headingEndMark"> — </span>The side effects of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> are generally similar. When used for the treatment of autoimmune disorders, the frequency and severity of side effects are lower compared with those seen in transplant recipients. This observation is explained by the lower doses used and the option to decrease the dose or discontinue the medication when toxicity appears in patients with autoimmune disorders; these options may not be available in transplant recipients.</p><p class="headingAnchor" id="H18"><span class="h2">Nephrotoxicity</span><span class="headingEndMark"> — </span>Nephrotoxicity is a significant adverse effect of both drugs. <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> nephrotoxicity is manifested as an acute increase in plasma creatinine, which is largely reversible after reducing the dose, or as chronic occasionally progressive kidney disease, which is usually irreversible. Other kidney effects of cyclosporine include tubular dysfunction and, rarely, a thrombotic microangiopathy (TMA). (See  <a class="medical medical_review" href="/z/d/html/7357.html" rel="external">"Cyclosporine and tacrolimus nephrotoxicity"</a>.)</p><p class="headingAnchor" id="H19"><span class="h2">Hypertension</span><span class="headingEndMark"> — </span>Hypertension, caused by renal vasoconstriction and sodium retention, generally develops within the first few weeks of therapy. Stimulation of the renal sodium chloride cotransporter is a potential mechanism by which calcineurin inhibitors may mediate this effect [<a href="#rid55">55</a>]. The blood pressure elevation usually responds to dose reduction, but antihypertensive medications may be required. (See  <a class="medical medical_review" href="/z/d/html/7357.html" rel="external">"Cyclosporine and tacrolimus nephrotoxicity"</a> and  <a class="medical medical_review" href="/z/d/html/7360.html" rel="external">"Hypertension after kidney transplantation", section on 'Approach to pharmacologic therapy'</a>.)</p><p>Calcium channel blockers are usually considered the drugs of choice if antihypertensive therapy is needed in the setting of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> therapy. As noted above, <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a> also impairs cyclosporine metabolism, thereby allowing a lower dose to be given. Initiation of diltiazem should prompt immediate reduction in the dose of cyclosporine or <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> and careful monitoring of blood concentrations. Diltiazem also reverses the acute vasoconstriction induced by cyclosporine; there is, however, no convincing evidence that this prevents chronic cyclosporine nephrotoxicity. (See  <a class="medical medical_review" href="/z/d/html/7357.html" rel="external">"Cyclosporine and tacrolimus nephrotoxicity", section on 'Prevention of chronic calcineurin inhibitor nephrotoxicity'</a>.)</p><p class="headingAnchor" id="H20"><span class="h2">Neurotoxicity</span><span class="headingEndMark"> — </span>Neurotoxicity associated with <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> may manifest as follows [<a href="#rid56">56-61</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Mild tremor is common with both <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> use, occurring in 35 to 55 percent of patients [<a href="#rid58">58,59</a>]. It may improve despite continued therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rarely, patients develop severe headache, visual abnormalities, and seizures. This syndrome is associated with acute hypertension and resembles hypertensive encephalopathy [<a href="#rid56">56</a>]. Posterior leukoencephalopathy is usually seen on brain imaging [<a href="#rid61">61</a>]. (See  <a class="medical medical_review" href="/z/d/html/4835.html" rel="external">"Reversible posterior leukoencephalopathy syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Akinetic mutism, encephalopathy, seizures, focal neurologic abnormalities, and even coma have been reported with intravenous <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> [<a href="#rid57">57</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A calcineurin-inhibitor pain syndrome has been reported with both <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> [<a href="#rid62">62</a>]. This syndrome is characterized by symmetrical pain in the lower limbs, usually involving the bones of the feet, ankles, and knees. Magnetic resonance imaging (MRI) may show marrow edema. Symptoms usually improve with cessation of the drug and/or use of calcium channel blockers.</p><p></p><p>The neurologic side effects are usually reversible following a change from intravenous to an oral preparation, lowering of the drug dose, or drug discontinuation [<a href="#rid56">56,57,60</a>]. They are generally more common with <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> than with <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> [<a href="#rid58">58,59</a>].</p><p class="headingAnchor" id="H21"><span class="h2">Metabolic abnormalities</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> have been associated with the following metabolic abnormalities:</p><p class="bulletIndent1"><span class="glyph">●</span>Glucose intolerance and diabetes mellitus (see  <a class="medical medical_review" href="/z/d/html/7327.html" rel="external">"Kidney transplantation in adults: Posttransplantation diabetes mellitus"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyperlipidemia (see  <a class="medical medical_review" href="/z/d/html/3521.html" rel="external">"Heart transplantation: Hyperlipidemia after transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/7303.html" rel="external">"Lipid abnormalities after kidney transplantation"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyperuricemia and gout (see  <a class="medical medical_review" href="/z/d/html/7297.html" rel="external">"Kidney transplantation in adults: Hyperuricemia and gout in kidney transplant recipients"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyperkalemia (see  <a class="medical medical_review" href="/z/d/html/7357.html" rel="external">"Cyclosporine and tacrolimus nephrotoxicity", section on 'Hyperkalemia'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypomagnesemia (see  <a class="medical medical_review" href="/z/d/html/7357.html" rel="external">"Cyclosporine and tacrolimus nephrotoxicity", section on 'Hypomagnesemia'</a>)</p><p></p><p><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> may also contribute to bone loss after organ transplantation [<a href="#rid63">63</a>]; this effect may be due to the induction of high bone turnover. (See  <a class="medical medical_review" href="/z/d/html/2036.html" rel="external">"Drugs that affect bone metabolism"</a> and  <a class="medical medical_review" href="/z/d/html/100623.html" rel="external">"Kidney transplantation in adults: Bone disease after kidney transplantation", section on 'Pathogenesis and risk factors'</a>.)</p><p class="headingAnchor" id="H22"><span class="h2">Infections</span><span class="headingEndMark"> — </span>Bacterial, viral (most often, cytomegalovirus [CMV]), and fungal infections often develop in transplant recipients receiving combined immunosuppressive therapy. In a large trial of liver transplant recipients comparing the efficacy and safety of cyclosporine- and tacrolimus-based immunosuppressive regimens, infection, sepsis, and CMV disease occurred in approximately 40, 20, and 15 to 25 percent of patients, respectively [<a href="#rid58">58</a>].</p><p>Infection in the solid organ transplant recipient is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1396.html" rel="external">"Infection in the solid organ transplant recipient"</a>.)</p><p class="headingAnchor" id="H23"><span class="h2">Risk of malignancy</span><span class="headingEndMark"> — </span>Both <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> are associated with an increased risk of squamous cell skin cancer and benign or malignant lymphoproliferative disorders. Spontaneous regression of lymphoma may occur if the drug is discontinued early. (See  <a class="medical medical_review" href="/z/d/html/7304.html" rel="external">"Malignancy after solid organ transplantation"</a>.)</p><p>The overall level of immunosuppression appears to be the principal factor that increases the risk of posttransplant malignancy. However, evidence from animal models suggests that <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> itself may promote cancer progression, principally via the production of transforming growth factor (TGF)-beta. In vitro, cyclosporine treatment of a normally noninvasive adenocarcinoma cell line induced an invasive phenotype; in addition, cyclosporine promoted tumor growth in immunodeficient animals [<a href="#rid64">64</a>]. Both the in vitro and in vivo changes were prevented by the administration of anti-TGF-beta antibodies.</p><p class="headingAnchor" id="H24"><span class="h2">Pregnancy and lactation</span><span class="headingEndMark"> — </span>The effects of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> on pregnancy and lactation are discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Cyclosporine'</a> and  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Tacrolimus'</a> and  <a class="medical medical_review" href="/z/d/html/113826.html" rel="external">"Sexual and reproductive health after kidney transplantation", section on 'Management of immunosuppression'</a>.)</p><p class="headingAnchor" id="H25"><span class="h2">Other side effects</span><span class="headingEndMark"> — </span>Other side effects associated with the use of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal</strong> – Gastrointestinal side effects include anorexia, nausea, vomiting, diarrhea, and abdominal discomfort. These symptoms are more frequent with <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> (72 versus 47 percent for <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> in one report) [<a href="#rid59">59</a>]. Elevated serum aminotransferase levels with mild hyperbilirubinemia may also occur; if present, this abnormality is reversible with dose reduction or discontinuation of the drug [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cosmetic</strong> – Gingival hyperplasia and hirsutism occur with <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> therapy [<a href="#rid66">66,67</a>] but not with <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>. Poor dental hygiene, higher doses of cyclosporine, and concomitant use of <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">nifedipine</a> appear to be the principal risks [<a href="#rid68">68</a>]. Case reports suggest that the gingival hyperplasia can be effectively treated with a two-week course of <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> (750 mg three times daily) while cyclosporine is continued [<a href="#rid69">69,70</a>]. It is not clear whether metronidazole acts in this setting via its antibacterial activity or via another mechanism. Treatment with <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> (500 mg/day for three consecutive days) may also be effective, particularly among those with mild or early disease [<a href="#rid71">71</a>]. In the transplant setting, the substitution of cyclosporine with tacrolimus was found to significantly ameliorate gingival hyperplasia without increasing the risk of kidney allograft dysfunction or rejection [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent1">An increasingly recognized complication of immunosuppressive therapy in transplant recipients is alopecia, a finding attributed, in one study, to the use of <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> [<a href="#rid73">73</a>]. At one transplant center, alopecia was noted in 3 to 6 percent of recipients receiving this agent [<a href="#rid74">74</a>]. Higher doses were associated with an increased risk. Another study reported an incidence of 30 percent among kidney-pancreas recipients who received tacrolimus [<a href="#rid75">75</a>].</p><p></p><p class="headingAnchor" id="H26"><span class="h1">CONTRAINDICATIONS</span><span class="headingEndMark"> — </span>Hypersensitivity to <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, or polyoxyl castor oil products (used as solvents for injection preparation of both drugs) is a contraindication to their use. The following conditions are generally accepted contraindications to the use of cyclosporine or tacrolimus:</p><p class="bulletIndent1"><span class="glyph">●</span>Concurrent malignancy (except for nonmelanoma skin carcinoma)</p><p class="bulletIndent1"><span class="glyph">●</span>Uncontrolled hypertension</p><p class="bulletIndent1"><span class="glyph">●</span>Uncontrolled infections</p><p class="bulletIndent1"><span class="glyph">●</span>Hypersensitivity</p><p></p><p class="headingAnchor" id="H7224195"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/583.html" rel="external">"Patient education: Disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/3439.html" rel="external">"Patient education: Heart transplantation (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H841472"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Formulations</strong> – <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> are immunosuppressive agents occasionally used in the treatment of various immune-mediated diseases and more commonly used to prevent rejection in solid organ transplantation; the drugs are available in oral, intravenous, ophthalmic, and topical formulations  (<a class="graphic graphic_table graphicRef57518" href="/z/d/graphic/57518.html" rel="external">table 1</a>). (See <a class="local">'Formulations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of action</strong> – <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> reduce T cell activation through the inhibition of calcineurin after forming complexes in the cytoplasm with cyclophilins and FK-binding proteins, respectively. Calcineurin inhibition results in reduced transcription of early cytokine genes, including those for interleukin (IL)-2, tumor necrosis factor (TNF), and several others. (See <a class="local">'Mechanism of action'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and administration</strong> – The dose, route, formulation, and drug concentrations of calcineurin inhibitors depend upon several factors. Routine blood monitoring is recommended. Many factors should be considered when making dose adjustments to calcineurin inhibitors. (See <a class="local">'Dose and administration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacokinetics</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Oral <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> are only partially absorbed, with large inter- and intra-individual variability. The oral bioavailability is limited for both drugs due to poor absorption, partial metabolism by enzymes in the bowel mucosa, and first-pass hepatic metabolism. The drugs are lipophilic and undergo extensive body distribution. Cyclosporine does not cross the blood-brain barrier. (See <a class="local">'Absorption'</a> above and <a class="local">'Distribution'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> are metabolized by hepatic cytochrome P-450 3A enzymes in the liver and are excreted into the bile. Liver dysfunction prolongs the half-life of both agents. A variety of important drug interactions with drugs that either affect or are metabolized by these enzymes can occur  (<a class="graphic graphic_table graphicRef110436" href="/z/d/graphic/110436.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef73326" href="/z/d/graphic/73326.html" rel="external">table 6</a>). Details about specific interactions are available by using the <a class="external" href="/drug-interactions">drug interaction program</a> included with UpToDate. (See <a class="local">'Metabolism'</a> above and <a class="local">'Elimination'</a> above and <a class="local">'Food and drug interactions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Side effects</strong> – The side effects of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> are similar. Nephrotoxicity is the most common and clinically significant adverse effect of both drugs. Hypertension, caused by renal vasoconstriction and sodium retention, is also common and generally develops within the first few weeks of therapy. Other potential adverse effects include neurotoxicity, metabolic abnormalities, infections, and an increased risk of malignancy. Contraindications to use depend upon the presence of various comorbidities or hypersensitivity to the agents. (See <a class="local">'Side effects'</a> above and  <a class="medical medical_review" href="/z/d/html/7357.html" rel="external">"Cyclosporine and tacrolimus nephrotoxicity"</a> and <a class="local">'Contraindications'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Wiederrecht G, Lam E, Hung S, et al. The mechanism of action of FK-506 and cyclosporin A. Ann N Y Acad Sci 1993; 696:9.</a></li><li><a class="nounderline abstract_t">Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992; 13:136.</a></li><li><a class="nounderline abstract_t">Kahan BD. Cyclosporine. N Engl J Med 1989; 321:1725.</a></li><li><a class="nounderline abstract_t">Klintmalm GB. FK 506: an update. Clin Transplant 1994; 8:207.</a></li><li><a class="nounderline abstract_t">Mochizuki M, Masuda K, Sakane T, et al. A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol 1993; 115:763.</a></li><li><a class="nounderline abstract_t">Jegasothy BV, Ackerman CD, Todo S, et al. Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol 1992; 128:781.</a></li><li><a class="nounderline abstract_t">Shin GT, Khanna A, Ding R, et al. In vivo expression of transforming growth factor-beta1 in humans: stimulation by cyclosporine. Transplantation 1998; 65:313.</a></li><li><a class="nounderline abstract_t">Slattery C, Campbell E, McMorrow T, Ryan MP. Cyclosporine A-induced renal fibrosis: a role for epithelial-mesenchymal transition. Am J Pathol 2005; 167:395.</a></li><li><a class="nounderline abstract_t">Ishida Y, Matsuda H, Kida K. Effect of cyclosporin A on human bone marrow granulocyte-macrophage progenitors with anti-cancer agents. Acta Paediatr Jpn 1995; 37:610.</a></li><li><a class="nounderline abstract_t">Spence MM, Nguyen LM, Hui RL, Chan J. Evaluation of clinical and safety outcomes associated with conversion from brand-name to generic tacrolimus in transplant recipients enrolled in an integrated health care system. Pharmacotherapy 2012; 32:981.</a></li><li><a class="nounderline abstract_t">Cabello M, García P, González-Molina M, et al. Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. Transplant Proc 2010; 42:3038.</a></li><li class="breakAll">http://www.veloxis.com/technology/cfm (Accessed on April 18, 2016).</li><li class="breakAll">Astagraf XL prescribing information 12/2015. http://www.astellas.us/docs/AstagrafXL.pdf (Accessed on April 13, 2016).</li><li><a class="nounderline abstract_t">Pennington CA, Park JM. Sublingual tacrolimus as an alternative to oral administration for solid organ transplant recipients. Am J Health Syst Pharm 2015; 72:277.</a></li><li class="breakAll">Astellas. ASTAGRAF XL. Effects of ethanol on the dissolution properties of tacrolimus extended-release study No. PCAR1301280. Data on file.</li><li class="breakAll">Prograf prescribing information 5/2015. http://www.astellas.us/docs/prograf.pdf (Accessed on January 06, 2020).</li><li><a class="nounderline abstract_t">Kamar N, Garrigue V, Karras A, et al. Impact of early or delayed cyclosporine on delayed graft function in renal transplant recipients: a randomized, multicenter study. Am J Transplant 2006; 6:1042.</a></li><li><a class="nounderline abstract_t">Lebranchu Y, Bridoux F, Büchler M, et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002; 2:48.</a></li><li><a class="nounderline abstract_t">Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 Suppl 3:S1.</a></li><li><a class="nounderline abstract_t">Budde K, Bunnapradist S, Grinyo JM, et al. Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial. Am J Transplant 2014; 14:2796.</a></li><li><a class="nounderline abstract_t">Levy G, Thervet E, Lake J, et al. Patient management by Neoral C(2) monitoring: an international consensus statement. Transplantation 2002; 73:S12.</a></li><li><a class="nounderline abstract_t">Thervet E, Pfeffer P, Scolari MP, et al. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion. Transplantation 2003; 76:903.</a></li><li><a class="nounderline abstract_t">Cole E, Maham N, Cardella C, et al. Clinical benefits of neoral C2 monitoring in the long-term management of renal transplant recipients. Transplantation 2003; 75:2086.</a></li><li><a class="nounderline abstract_t">Cantarovich M, Barkun JS, Tchervenkov JI, et al. Comparison of neoral dose monitoring with cyclosporine through levels versus 2-hr postdose levels in stable liver transplant patients. Transplantation 1998; 66:1621.</a></li><li><a class="nounderline abstract_t">Anglicheau D, Verstuyft C, Laurent-Puig P, et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 2003; 14:1889.</a></li><li><a class="nounderline abstract_t">Thervet E, Anglicheau D, King B, et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 2003; 76:1233.</a></li><li><a class="nounderline abstract_t">Tsuchiya N, Satoh S, Tada H, et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 2004; 78:1182.</a></li><li><a class="nounderline abstract_t">Gervasini G, Garcia M, Macias RM, et al. Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation. Transpl Int 2012; 25:471.</a></li><li><a class="nounderline abstract_t">Singh R, Srivastava A, Kapoor R, Mittal RD. Do drug transporter (ABCB1) SNPs influence cyclosporine and tacrolimus dose requirements and renal allograft outcome in the posttransplantation period? J Clin Pharmacol 2011; 51:603.</a></li><li><a class="nounderline abstract_t">Pallet N, Etienne I, Buchler M, et al. Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype. Am J Transplant 2016; 16:2670.</a></li><li><a class="nounderline abstract_t">Alloway R, Steinberg S, Khalil K, et al. Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen. Transplant Proc 2005; 37:867.</a></li><li><a class="nounderline abstract_t">van Hooff J, Van der Walt I, Kallmeyer J, et al. Pharmacokinetics in stable kidney transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations. Ther Drug Monit 2012; 34:46.</a></li><li><a class="nounderline abstract_t">Florman S, Alloway R, Kalayoglu M, et al. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen. Transplant Proc 2005; 37:1211.</a></li><li><a class="nounderline abstract_t">Zhang YF, Chen XY, Dai XJ, et al. Pharmacokinetics of tacrolimus converted from twice-daily formulation to once-daily formulation in Chinese stable liver transplant recipients. Acta Pharmacol Sin 2011; 32:1419.</a></li><li><a class="nounderline abstract_t">Heffron TG, Pescovitz MD, Florman S, et al. Once-daily tacrolimus extended-release formulation: 1-year post-conversion in stable pediatric liver transplant recipients. Am J Transplant 2007; 7:1609.</a></li><li><a class="nounderline abstract_t">Alloway R, Vanhaecke J, Yonan N, et al. Pharmacokinetics in stable heart transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations. J Heart Lung Transplant 2011; 30:1003.</a></li><li class="breakAll">Envarsus XR prescribing information 6/2015 http:www/envarsusxr.com/files/1814/4899/3398/EnvarsusXR_PI_8_4_15.pdf (Accessed on April 13, 2016).</li><li><a class="nounderline abstract_t">Doligalski CT, Liu EC, Sammons CM, et al. Sublingual administration of tacrolimus: current trends and available evidence. Pharmacotherapy 2014; 34:1209.</a></li><li><a class="nounderline abstract_t">Kolars JC, Awni WM, Merion RM, Watkins PB. First-pass metabolism of cyclosporin by the gut. Lancet 1991; 338:1488.</a></li><li><a class="nounderline abstract_t">Hooks MA. Tacrolimus, a new immunosuppressant--a review of the literature. Ann Pharmacother 1994; 28:501.</a></li><li><a class="nounderline abstract_t">Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997; 62:248.</a></li><li><a class="nounderline abstract_t">Yigitaslan S, Erol K, Cengelli C. The Effect of P-Glycoprotein Inhibition and Activation on the Absorption and Serum Levels of Cyclosporine and Tacrolimus in Rats. Adv Clin Exp Med 2016; 25:237.</a></li><li><a class="nounderline abstract_t">Mancinelli LM, Frassetto L, Floren LC, et al. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther 2001; 69:24.</a></li><li><a class="nounderline abstract_t">Oetting WS, Schladt DP, Guan W, et al. Genomewide Association Study of Tacrolimus Concentrations in African American Kidney Transplant Recipients Identifies Multiple CYP3A5 Alleles. Am J Transplant 2016; 16:574.</a></li><li><a class="nounderline abstract_t">García-Roca P, Medeiros M, Reyes H, et al. CYP3A5 polymorphism in Mexican renal transplant recipients and its association with tacrolimus dosing. Arch Med Res 2012; 43:283.</a></li><li><a class="nounderline abstract_t">Jacobson PA, Oetting WS, Brearley AM, et al. Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. Transplantation 2011; 91:300.</a></li><li><a class="nounderline abstract_t">Bekersky I, Dressler D, Mekki Q. Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose. J Clin Pharmacol 2001; 41:289.</a></li><li><a class="nounderline abstract_t">Small DS, Acheampong A, Reis B, et al. Blood concentrations of cyclosporin a during long-term treatment with cyclosporin a ophthalmic emulsions in patients with moderate to severe dry eye disease. J Ocul Pharmacol Ther 2002; 18:411.</a></li><li><a class="nounderline abstract_t">Olson KA, West K, McCarthy PL. Toxic tacrolimus levels after application of topical tacrolimus and use of occlusive dressings in two bone marrow transplant recipients with cutaneous graft-versus-host disease. Pharmacotherapy 2014; 34:e60.</a></li><li><a class="nounderline abstract_t">Bramham K, Chusney G, Lee J, et al. Breastfeeding and tacrolimus: serial monitoring in breast-fed and bottle-fed infants. Clin J Am Soc Nephrol 2013; 8:563.</a></li><li><a class="nounderline abstract_t">Amioka K, Kuzuya T, Kushihara H, et al. Carvedilol increases ciclosporin bioavailability by inhibiting P-glycoprotein-mediated transport. J Pharm Pharmacol 2007; 59:1383.</a></li><li><a class="nounderline abstract_t">Wang J, Huang L, Gao P, et al. Diltiazem on tacrolimus exposure and dose sparing in Chinese pediatric primary nephrotic syndrome: impact of CYP3A4, CYP3A5, ABCB1, and SLCO1B3 polymorphisms. Eur J Clin Pharmacol 2021; 77:71.</a></li><li><a class="nounderline abstract_t">Méndez S, Ramay BM, Aguilar-González A, Lou-Meda R. Exploring the safety and efficacy of adding ketoconazole to tacrolimus in pediatric renal transplant immunosuppression. World J Transplant 2020; 10:356.</a></li><li><a class="nounderline abstract_t">Chisholm MA, Mulloy LL, Jagadeesan M, DiPiro JT. Coadministration of tacrolimus with anti-acid drugs. Transplantation 2003; 76:665.</a></li><li><a class="nounderline abstract_t">Hoorn EJ, Walsh SB, McCormick JA, et al. The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. Nat Med 2011; 17:1304.</a></li><li><a class="nounderline abstract_t">Schwartz RB, Bravo SM, Klufas RA, et al. Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases. AJR Am J Roentgenol 1995; 165:627.</a></li><li><a class="nounderline abstract_t">Eidelman BH, Abu-Elmagd K, Wilson J, et al. Neurologic complications of FK 506. Transplant Proc 1991; 23:3175.</a></li><li><a class="nounderline abstract_t">Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet 1994; 344:423.</a></li><li><a class="nounderline abstract_t">U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331:1110.</a></li><li><a class="nounderline abstract_t">Wijdicks EF, Wiesner RH, Krom RA. Neurotoxicity in liver transplant recipients with cyclosporine immunosuppression. Neurology 1995; 45:1962.</a></li><li><a class="nounderline abstract_t">Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996; 334:494.</a></li><li><a class="nounderline abstract_t">Prommer E. Calcineurin-inhibitor pain syndrome. Clin J Pain 2012; 28:556.</a></li><li><a class="nounderline abstract_t">Thiébaud D, Krieg MA, Gillard-Berguer D, et al. Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation. Eur J Clin Invest 1996; 26:549.</a></li><li><a class="nounderline abstract_t">Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397:530.</a></li><li><a class="nounderline abstract_t">Landewe RB, Goei The HS, van Rijthoven AW, et al. Cyclosporine in common clinical practice: an estimation of the benefit/risk ratio in patients with rheumatoid arthritis. J Rheumatol 1994; 21:1631.</a></li><li><a class="nounderline abstract_t">Dongari A, McDonnell HT, Langlais RP. Drug-induced gingival overgrowth. Oral Surg Oral Med Oral Pathol 1993; 76:543.</a></li><li><a class="nounderline abstract_t">Cutolo M, Giusti M, Villaggio B, et al. Testosterone metabolism and cyclosporin A treatment in rheumatoid arthritis. Br J Rheumatol 1997; 36:433.</a></li><li><a class="nounderline abstract_t">Thomas DW, Newcombe RG, Osborne GR. Risk factors in the development of cyclosporine-induced gingival overgrowth. Transplantation 2000; 69:522.</a></li><li><a class="nounderline abstract_t">Wong W, Hodge MG, Lewis A, et al. Resolution of cyclosporin-induced gingival hypertrophy with metronidazole. Lancet 1994; 343:986.</a></li><li><a class="nounderline abstract_t">Cecchin E, Zanello F, De Marchi S. Treatment of cyclosporine-induced gingival hypertrophy. Ann Intern Med 1997; 126:409.</a></li><li><a class="nounderline abstract_t">Gómez E, Sánchez-Nuñez M, Sánchez JE, et al. Treatment of cyclosporin-induced gingival hyperplasia with azithromycin. Nephrol Dial Transplant 1997; 12:2694.</a></li><li><a class="nounderline abstract_t">Thorp M, DeMattos A, Bennett W, et al. The effect of conversion from cyclosporine to tacrolimus on gingival hyperplasia, hirsutism and cholesterol. Transplantation 2000; 69:1218.</a></li><li><a class="nounderline abstract_t">Talbot D, Rix D, Abusin K, et al. Alopecia as a consequence of tacrolimus therapy in renal transplantation? Transplantation 1997; 64:1631.</a></li><li><a class="nounderline abstract_t">Shapiro R, Jordan ML, Scantlebury VP, et al. Alopecia as a consequence of tacrolimus therapy. Transplantation 1998; 65:1284.</a></li><li><a class="nounderline abstract_t">Tricot L, Lebbé C, Pillebout E, et al. Tacrolimus-induced alopecia in female kidney-pancreas transplant recipients. Transplantation 2005; 80:1546.</a></li></ol></div><div id="topicVersionRevision">Topic 7995 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7509138" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The mechanism of action of FK-506 and cyclosporin A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1374612" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The mechanism of action of cyclosporin A and FK506.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2687689" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cyclosporine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7517226" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : FK 506: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7685147" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A clinical trial of FK506 in refractory uveitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1376102" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9484745" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : In vivo expression of transforming growth factor-beta1 in humans: stimulation by cyclosporine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16049326" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Cyclosporine A-induced renal fibrosis: a role for epithelial-mesenchymal transition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8533588" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Effect of cyclosporin A on human bone marrow granulocyte-macrophage progenitors with anti-cancer agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23074134" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Evaluation of clinical and safety outcomes associated with conversion from brand-name to generic tacrolimus in transplant recipients enrolled in an integrated health care system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20970603" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20970603" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20970603" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25631834" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Sublingual tacrolimus as an alternative to oral administration for solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25631834" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Sublingual tacrolimus as an alternative to oral administration for solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25631834" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Sublingual tacrolimus as an alternative to oral administration for solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16611342" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Impact of early or delayed cyclosporine on delayed graft function in renal transplant recipients: a randomized, multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12095056" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19845597" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : KDIGO clinical practice guideline for the care of kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25278376" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12023608" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Patient management by Neoral C(2) monitoring: an international consensus statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14508352" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12829917" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Clinical benefits of neoral C2 monitoring in the long-term management of renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9884249" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Comparison of neoral dose monitoring with cyclosporine through levels versus 2-hr postdose levels in stable liver transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12819250" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14578760" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15502717" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22369694" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20571034" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Do drug transporter (ABCB1) SNPs influence cyclosporine and tacrolimus dose requirements and renal allograft outcome in the posttransplantation period?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26990694" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15848559" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22249344" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Pharmacokinetics in stable kidney transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15848672" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21963896" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Pharmacokinetics of tacrolimus converted from twice-daily formulation to once-daily formulation in Chinese stable liver transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17511684" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Once-daily tacrolimus extended-release formulation: 1-year post-conversion in stable pediatric liver transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21493098" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Pharmacokinetics in stable heart transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21493098" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Pharmacokinetics in stable heart transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25251980" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Sublingual administration of tacrolimus: current trends and available evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1683920" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : First-pass metabolism of cyclosporin by the gut.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7518710" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Tacrolimus, a new immunosuppressant--a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9333100" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27627555" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The Effect of P-Glycoprotein Inhibition and Activation on the Absorption and Serum Levels of Cyclosporine and Tacrolimus in Rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11180035" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26485092" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Genomewide Association Study of Tacrolimus Concentrations in African American Kidney Transplant Recipients Identifies Multiple CYP3A5 Alleles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22704849" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : CYP3A5 polymorphism in Mexican renal transplant recipients and its association with tacrolimus dosing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21206424" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11269569" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12419092" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Blood concentrations of cyclosporin a during long-term treatment with cyclosporin a ophthalmic emulsions in patients with moderate to severe dry eye disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24700567" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Toxic tacrolimus levels after application of topical tacrolimus and use of occlusive dressings in two bone marrow transplant recipients with cutaneous graft-versus-host disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23349333" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Breastfeeding and tacrolimus: serial monitoring in breast-fed and bottle-fed infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17910813" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Carvedilol increases ciclosporin bioavailability by inhibiting P-glycoprotein-mediated transport.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32803289" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Diltiazem on tacrolimus exposure and dose sparing in Chinese pediatric primary nephrotic syndrome: impact of CYP3A4, CYP3A5, ABCB1, and SLCO1B3 polymorphisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33312896" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Exploring the safety and efficacy of adding ketoconazole to tacrolimus in pediatric renal transplant immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12973105" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Coadministration of tacrolimus with anti-acid drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21963515" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7645483" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1721398" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Neurologic complications of FK 506.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7520105" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7523946" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7501141" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Neurotoxicity in liver transplant recipients with cyclosporine immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8559202" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A reversible posterior leukoencephalopathy syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22673490" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Calcineurin-inhibitor pain syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8864416" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10028970" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Cyclosporine induces cancer progression by a cell-autonomous mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7799340" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Cyclosporine in common clinical practice: an estimation of the benefit/risk ratio in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8233439" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Drug-induced gingival overgrowth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9159535" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Testosterone metabolism and cyclosporin A treatment in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10708105" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Risk factors in the development of cyclosporine-induced gingival overgrowth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7909047" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Resolution of cyclosporin-induced gingival hypertrophy with metronidazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9054291" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Treatment of cyclosporine-induced gingival hypertrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9430874" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Treatment of cyclosporin-induced gingival hyperplasia with azithromycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10762229" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : The effect of conversion from cyclosporine to tacrolimus on gingival hyperplasia, hirsutism and cholesterol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9415574" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Alopecia as a consequence of tacrolimus therapy in renal transplantation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9603186" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Alopecia as a consequence of tacrolimus therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16371923" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Tacrolimus-induced alopecia in female kidney-pancreas transplant recipients.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
